Literature DB >> 1500527

Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with Shigella sonnei.

N Orr1, G Robin, G Lowell, D Cohen.   

Abstract

The appearance of antigen-specific immunoglobulin A (IgA) antibody-secreting cells (ASCs) following natural infection with Shigella sonnei during a common-source outbreak caused by this organism was evaluated in a modified enzyme-linked immunosorbent assay (ELISPOT). A mean IgA ASC value of 2,131.6/10(6) cells against homologous S. sonnei lipopolysaccharide (LPS) was detected in blood samples obtained from patients with bacteriologically proven S. sonnei shigellosis 5 and 10 days after the onset of disease. In the same blood samples, the level of ASC measured against heterologous antigen (Shigella flexneri serotype 2a LPS) was significantly lower than that of the homologous antigen (mean value, 33.12/10(6) cells). Furthermore, the mean number of activated B cells that secreted anti-S. sonnei LPS antibodies was significantly higher among patients with S. sonnei shigellosis than it was among patients with non-Shigella diarrhea (2.5/10(6) cells; standard error, 1.0) and healthy subjects (5.1/10(6) cells; standard error, 2.3) (P less than 0.05). The anti-LPS IgA ASC activity was easily detected within 5 days of the onset of disease, a point at which the levels of anti-S. sonnei LPS IgG and even IgA antibodies were hardly detectable in serum.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500527      PMCID: PMC265463          DOI: 10.1128/jcm.30.8.2165-2168.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Immune response to acute diarrhea seen as circulating antibody-secreting cells.

Authors:  A M Kantele; R Takanen; H Arvilommi
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

2.  Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections.

Authors:  D Cohen; C Block; M S Green; G Lowell; I Ofek
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

3.  Natural and recombinant interferons inhibit epithelial cell invasion by Shigella spp.

Authors:  D W Niesel; C B Hess; Y J Cho; K D Klimpel; G R Klimpel
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

4.  Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection.

Authors:  H L DuPont; R B Hornick; M J Snyder; J P Libonati; S B Formal; E J Gangarosa
Journal:  J Infect Dis       Date:  1972-01       Impact factor: 5.226

5.  Identification of an intestinal immune response using peripheral blood lymphocytes.

Authors:  B D Forrest
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

6.  Direct demonstration in intestinal secretions of an IgA memory response to orally administered Shigella flexneri antigens.

Authors:  D F Keren; S E Kern; D H Bauer; P J Scott; P Porter
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

7.  Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei.

Authors:  L Van de Verg; D A Herrington; J R Murphy; S S Wasserman; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Intestinal immunoglobulin A responses in rabbits to a Salmonella typhi strain harboring a Shigella sonnei plasmid.

Authors:  D F Keren; H H Collins; L S Baron; D J Kopecko; S B Formal
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

9.  Antibody-dependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against shigella.

Authors:  G H Lowell; R P MacDermott; P L Summers; A A Reeder; M J Bertovich; S B Formal
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

10.  T-lymphocyte clones responsive to Shigella flexneri.

Authors:  S H Zwillich; A D Duby; P E Lipsky
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

View more
  11 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.

Authors:  Nadav Orr; David E Katz; Jacob Atsmon; Paull Radu; Miri Yavzori; Tamar Halperin; Tamar Sela; Raid Kayouf; Zivit Klein; Ruhama Ambar; Dani Cohen; Marcia K Wolf; Malabi M Venkatesan; Thomas L Hale
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

Authors:  D Cohen; S Ashkenazi; M Green; Y Lerman; R Slepon; G Robin; N Orr; D N Taylor; J C Sadoff; C Chu; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity.

Authors:  V Rasolofo-Razanamparany; A M Cassel-Beraud; J Roux; P J Sansonetti; A Phalipon
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

5.  Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.

Authors:  F Qadri; C Wennerås; M J Albert; J Hossain; K Mannoor; Y A Begum; G Mohi; M A Salam; R B Sack; A M Svennerholm
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

6.  Thymic independence of adaptive immunity to the intracellular pathogen Shigella flexneri serotype 2a.

Authors:  S S Way; A C Borczuk; M B Goldberg
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

7.  ELISPOT assay for Chlamydia-specific, antibody-producing cells correlated with conventional complement fixation and microimmunofluorescence.

Authors:  H Daugharty; T O Messmer; B S Fields
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

8.  Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea.

Authors:  Anuradha Sinha; Ayan Dey; Giulietta Saletti; Pradip Samanta; Partha Sarathi Chakraborty; M K Bhattacharya; Santanu Ghosh; T Ramamurthy; Jae-Ouk Kim; Jae Seung Yang; Dong Wook Kim; Cecil Czerkinsky; Ranjan K Nandy
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

9.  Establishment of a Shigella sonnei human challenge model in Thailand.

Authors:  Ladaporn Bodhidatta; Punnee Pitisuttithum; Supat Chamnanchanant; Karen T Chang; Dilara Islam; Valai Bussaratid; Malabi M Venkatesan; Thomas L Hale; Carl J Mason
Journal:  Vaccine       Date:  2012-10-12       Impact factor: 3.641

10.  Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans.

Authors:  Franklin R Toapanta; Jakub K Simon; Eileen M Barry; Marcela F Pasetti; Myron M Levine; Karen L Kotloff; Marcelo B Sztein
Journal:  Front Immunol       Date:  2014-08-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.